by Society of Nuclear Medicine Representative PET images of 89ZrDFO-trastuzumab displaying %ID/g acquired 48 hours after radiolabeled trastuzumab injection on day 39 for T-DM1 single-treatment regime, T-DM1/statin single-treatment regime, T-DM1 multiple-treatment regime, and T-DM1/statin multiple-treatment regime. Tumor location is indicated by arrow. Credit: Journal of Nuclear Medicine (2023). DOI: 10.2967/jnumed.122.265172A novel therapeutic approach that combines human epidermal...
